Beata Dobracka
Overview
Explore the profile of Beata Dobracka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dabrowska M, Jaroszewicz J, Sitko M, Janocha-Litwin J, Zarebska-Michaluk D, Janczewska E, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272972
Background: Over the past years, the introduction of direct-acting antivirals (DAAs) revolutionized chronic hepatitis C treatment. We aimed to characterize and assess treatment efficacy in three specific groups of patients...
2.
Piekarska A, Berkan-Kawinska A, Berak H, Mazur W, Sitko M, Parfieniuk-Kowerda A, et al.
Expert Rev Anti Infect Ther
. 2024 May;
22(9):775-780.
PMID: 38722307
Background: The aim of this study was to evaluate the real-life efficacy of pangenotypic antivirals in HIV-HCV-positive patients. Research Design And Methods: The analysis included 5650 subjects who were treated...
3.
Dobrowolska K, Pawlowska M, Zarebska-Michaluk D, Rzymski P, Janczewska E, Tudrujek-Zdunek M, et al.
J Viral Hepat
. 2024 Mar;
31(6):309-319.
PMID: 38483035
Eliminating hepatitis C virus (HCV) infection in the population of women of reproductive age is important not only for the health of women themselves but also for the health of...
4.
Zarebska-Michaluk D, Flisiak R, Janczewska E, Berak H, Mazur W, Janocha-Litwin J, et al.
Antiviral Res
. 2023 Nov;
220:105742.
PMID: 37944825
Background & Aims: The study aimed to assess the phenomenon of achieving sustained virologic response (SVR) in patients with detectable ribonucleic acid (RNA) of hepatitis C virus (HCV) at the...
5.
Zarebska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawlowska M, et al.
J Clin Med
. 2021 Aug;
10(15).
PMID: 34362064
There is still limited data available from real-world experience studies on the pangenotypic regimens in patients with genotype (GT) 3 hepatitis C virus (HCV) infection and liver cirrhosis. The current...
6.
Janczewska E, Franciszek Kolek M, Lorenc B, Klapaczynski J, Tudrujek-Zdunek M, Sitko M, et al.
World J Gastroenterol
. 2021 May;
27(18):2177-2192.
PMID: 34025072
Background: The introduction of direct-acting antiviral drugs into clinical practice has revolutionized the treatment of chronic hepatitis C, making it highly effective and safe for patients. However, few researchers have...
7.
Tronina O, Durlik M, Orlowska I, Lorenc B, Lapinski T, Garlicki A, et al.
Ann Gastroenterol
. 2021 May;
34(3):438-446.
PMID: 33948071
Background: Patients who undergo hemodialysis (HD) or kidney transplantation (KTx) previously had limited possibilities for treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals (DAA) give these patients a chance...
8.
Berkan-Kawinska A, Piekarska A, Janczewska E, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, et al.
Liver Int
. 2021 Mar;
41(8):1789-1801.
PMID: 33655628
Background And Aims: The aim of this study was to assess the real-life effectiveness and safety of direct acting antivirals (DAAs) in patients with cirrhosis and history of hepatic decompensation...
9.
Zarebska-Michaluk D, Jaroszewicz J, Pabjan P, Lapinski T, Mazur W, Krygier R, et al.
J Gastroenterol Hepatol
. 2020 Nov;
36(7):1944-1952.
PMID: 33171526
Background And Aims: The revolution of the antiviral treatment of hepatitis C virus (HCV) infection resulting in higher effectiveness came with the introduction of direct-acting antivirals with pangenotypic regimens as...
10.
Jaroszewicz J, Pawlowska M, Simon K, Zarebska-Michaluk D, Lorenc B, Klapaczynski J, et al.
Expert Rev Anti Infect Ther
. 2020 Jun;
18(10):1045-1054.
PMID: 32538232
Objectives: The aim of the study was to analyze the prevalence and clinical characteristics of HCV/HBV coinfection and to evaluate the rate of HBV-reactivation during anti-HCV therapy in a large...